Developer docs
API playgroundTry for free, no card

Search company profiles

VivoSense

Full company profile

uuid00021di

Namestring
VivoSense
Legal namestring
VivoSense, Inc.
Websiteurl
vivosense.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

VivoSense, Inc. is a privately held, specialized Wearable Sensor Contract Research Organization (CRO) founded in 2010 and headquartered in Newport Coast, California. The company serves pharmaceutical sponsors, biotech firms, traditional CROs, and digital health innovators by providing end-to-end services for implementing wearable and connected digital health technologies (DHTs) in clinical trials. These services span three integrated phases: Study Startup (DHT strategy, sensor selection, protocol development), Study Conduct (device operationalization, monitoring, data collection, and transfer), and Study Closeout (data investigation, statistical analysis, and clinical validation). Named customer engagements include argenx (Phase 3b case study presented at the 2025 Digital Biomarkers Summit), Genentech/Roche (Clinical Trial Innovation Summit collaboration), GSK, RSRT, Boston Children's Hospital, Biogen, Mayo Clinic, and Newron.

The company's core technology is a proprietary, device-agnostic, cloud-based DHT platform that ingests, cleans, synchronizes, analyzes, and interprets wearable sensor data. The platform is described as compliant and auditable for use in regulated clinical trial environments and is paired with deep domain expertise across more than 70 wearable sensors, 20 therapeutic areas, and operations spanning 30+ countries. A flagship productized asset is MEADOW-RETT-BR, a DHT-based measure of apnea events in Rett syndrome patients co-developed with the Rett Syndrome Research Trust and Boston Children's Hospital, which received positive feedback from the EMA Innovation Task Force in December 2024.

VivoSense operates a B2B professional services revenue model with project-based, quote-determined pricing tied to study scope, duration, sensor requirements, and geographic reach. The company has raised approximately $27 million across its lifetime, including a $25 million Series A in March 2022 led by Perceptive Xontogeny Venture Fund and Debiopharm Innovation Fund. Distribution is exclusively direct enterprise sales, supported by thought leadership content (website, blogs, eBooks, webinars, peer-reviewed publications in journals such as Karger Digital Biomarkers and Frontiers in Digital Health) and active participation in industry coalitions including DiMe, DATAcc, FNIH, CTTI, CancerX, and ISPOR. Leadership comprises co-founder and CEO Dudley Tabakin, CSO Kate Lyden PhD, CTO Doug McAllister, Chief Algorithm Officer Ralf Hempfling, and functional VPs across sales, marketing, finance, engineering, science, quality, and clinical operations.

Short descriptiontext

VivoSense is a specialized wearable sensor Contract Research Organization serving pharmaceutical sponsors, biotech firms, and digital health innovators with end-to-end wearable sensor implementation and digital endpoint services across clinical trials. Its proprietary cloud-based DHT platform and 14+ years of expertise support trials in 30+ countries and 20+ therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewport Coast, United States
HQ citystring
Newport Coast
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable sensor CRO, digital health technology, clinical trial services, digital endpoint development, wearable sensor analytics
Industry2 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Services (Wearable Sensor CRO)
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Wearable Sensor CRO Services
TypeProfessional Services
Description

VivoSense generates revenue through providing end-to-end services for wearable sensor implementation in clinical trials. This includes DHT strategy consulting, sensor selection and operationalization, data collection and cleaning, and clinical validation services. The revenue model is project-based and service-oriented, working with pharmaceutical sponsors across clinical trial phases.

vivosense.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

VivoSense operates as a dedicated Wearable Sensor Contract Research Organization (CRO), providing end-to-end services and a proprietary cloud-based Digital Health Technology (DHT) platform for implementing wearable and connected digital health technologies in clinical trials. Its offering spans Study Startup (DHT strategy, measure selection, protocol development), Study Conduct (operationalization, monitoring, data collection, data transfer), and Study Closeout (data investigation, statistical analyses, clinical validation) for pharmaceutical sponsors, traditional CROs, and digital health innovators across more than 30 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 99% data availability achieved in cystic fibrosis trial with 200 devices across 18 sites worldwide
+4 more records
Product overview1 text field

VivoSense operates as a Wearable Sensor Contract Research Organization (CRO) providing end-to-end services for wearable and connected digital health technologies in clinical trials. The company offers its proprietary VivoSense DHT Platform as the core technology infrastructure, complemented by three integrated service phases: Study Startup (DHT Strategy, Measure Selection, and Protocol Development), Study Conduct (DHT Operationalization, Monitoring, Data Collection, and Data Transfer), and Study Closeout (DHT Data Investigation, Statistical Analyses, and Clinical Validation). The company also develops specific digital health measures such as MEADOW-RETT-BR for rare disease applications. This unified platform-plus-services model enables pharmaceutical sponsors to integrate wearable sensor technologies throughout the clinical development lifecycle.

Product and service5 records
1VivoSense DHT Platform
CategoryPlatform / Software
Description

VivoSense's proprietary cloud platform for managing digital health technology implementation in clinical trials. It serves as a centralized location for DHT-related activities including data collection, cleaning, monitoring, analysis, and reporting, providing a compliant and auditable solution for wearable sensor data. Sold as part of VivoSense's wearable sensor CRO service engagements with pharmaceutical sponsors.

2Study Startup Services
CategoryClinical Research Service
Description

DHT Strategy, Measure Selection, and Protocol Development services including sensor recommendation based on study needs and data quality, design of data collection and processing procedures, and digital health technology vendor relationship management to streamline clinical operations. Sold as part of VivoSense's wearable sensor CRO service engagements with pharmaceutical sponsors.

3Study Conduct Services
CategoryClinical Research Service
Description

DHT Operationalization, Monitoring, Data Collection, and Data Transfer services utilizing the VivoSense Platform for device deployment, site training, compliance tracking, and continuous data capture and cleaning. Sold as part of VivoSense's wearable sensor CRO service engagements with pharmaceutical sponsors.

4Study Closeout Services
CategoryClinical Research Service
Description

DHT Data Investigation, Statistical Analyses, and Clinical Validation services including feasibility assessment, treatment response evaluation, clinical validity establishment, and regulatory-ready reporting. Sold as part of VivoSense's wearable sensor CRO service engagements with pharmaceutical sponsors.

5MEADOW-RETT-BR Digital Health Measure
CategoryDigital Health Measure / Digital Endpoint
Description

MEADOW-RETT-BR is an innovative digital health technology-based measure of apnea events in patients with Rett syndrome, developed by VivoSense with the Rett Syndrome Research Trust and Boston Children's Hospital and currently undergoing EMA qualification for regulatory acceptance. It represents a specific digital endpoint that VivoSense develops and validates for rare disease applications.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-01
Description

CEO Dudley Tabakin presented at OCT UK & Ireland 2026 conference in London, discussing barriers to wearable adoption in clinical trials and achieving regulatory acceptance for digital endpoints.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Strategic partnership for end-to-end wearable sensor CRO services. Presented joint case study at 2025 Digital Biomarkers Summit showcasing how VivoSense's operational oversight improved Phase 3b study outcomes to 95.3% valid data days. Partnership spans strategy development, measure selection, operationalization, and regulatory strategy.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-06-01
Description

Host venue for the 8th Annual Digital Biomarkers in Clinical Trials Summit 2025. VivoSense and argenx presented joint case study at this flagship industry event.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Partner in MEADOW-RETT-BR digital health measure qualification for Rett syndrome. Collaboration focused on developing DHT-based measure of apnea events to support regulatory qualification with EMA and advance novel therapies for rare disease.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Clinical partner in MEADOW-RETT-BR measure development for Rett syndrome. Working with VivoSense and RSRT on qualification of DHT-based apnea measurement with EMA Innovation Task Force.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

CEO Dudley Tabakin led panel at Genentech's Clinical Trial Innovation Summit. Collaboration on digital biomarker implementation discussions with GSK and gRED representatives. VivoSense presented on the Wearable Sensor CRO model and digital measure adoption.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Dr. Sachin Shah, Digital Biomarker Lead at GSK, participated in Genentech panel with VivoSense CEO, discussing operational demands of wearable sensor data at scale and regulatory submission approaches.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

VivoSense joined DATAcc DiMe project 'Building the Business Case for Digital Endpoints' - a joint collaboration between DiMe and FDA. Contributed to Digital Endpoints ROI Calculator, Value Framework, and Case Study Catalog. Active contributor to DiMe Projects including Playbook, Core Measures of Physical Activity, and Core Measures of Sleep.

9DATAcc (Digital Health Measurement Collaborative Community)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Collaborative community with FDA's Center for Devices and Radiological Health. VivoSense contributes to establishing shared industry benchmarks for evaluating ROI of digital endpoints in drug development. Partner includes Tufts and FDA.

vivosense.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VivoSense is a member of both the Cancer and Neuroscience FNIH Biomarker Steering Committees. FNIH connects leading public and private organizations to accelerate biomedical breakthroughs through the Biomarkers Consortium.

11CTTI (Clinical Trials Transformation Initiative)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VivoSense is committed to CTTI's mission to build better, faster clinical trials. CTTI convenes 80+ members and 500+ multi-stakeholder organizations to develop and drive adoption of practices increasing clinical trial quality and efficiency.

vivosense.com
12CancerX
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Public-private partnership to boost innovation in cancer. Co-hosted by Moffitt Cancer Center and DiMe, alongside ONC and OASH. VivoSense participates to advance digital health technologies in oncology research.

vivosense.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

VivoSense participates in ISPOR, the leading global scientific organization for health economics and outcomes research. Promotes HEO/R excellence to improve decision-making for health globally.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Enterprise clinical trial platform owned by Dassault Systèmes with sensor ingestion, eCOA, and decentralized trial capabilities via Rave. Competes with VivoSense at the platform layer for wearable data capture and analysis in pharma-sponsored trials.

TypeBroad incumbent
Description

World's largest CRO with expanding digital health, real-world evidence, and connected device capabilities. Overlaps with VivoSense in wearable sensor deployment and digital endpoint services, particularly across large global Phase III programs.

TypeBroad incumbent
Description

Top-tier global CRO with a growing digital endpoints and decentralized trials practice (post-PRA Health and Symphony Clinical Research integrations). Broad incumbent competing for the same wearable CRO budgets as VivoSense.

TypeEmerging player
Description

Decentralized clinical trial technology platform with integrated eCOA, ePRO, and connected device / wearable sensor modules. Competes with VivoSense in enabling sponsors to operationalize wearable data in clinical trials, though more platform- and less service-led.

TypeBroad incumbent
Description

Large clinical trial technology company (formed from ERT and Bioclinica) offering eCOA, imaging, and increasingly wearable sensor / digital endpoint solutions to pharma sponsors. Broad incumbent competing with VivoSense in the digital endpoint layer of clinical trials.

TypeOthers
Description

Real-world health data and digital measurement platform leveraging wearables and connected devices, with applications in clinical research and patient-generated evidence. Thematically adjacent to VivoSense's wearable data business, primarily outside the regulated clinical trial endpoint layer.

TypeDirect peer
Description

Wearable sensor hardware and analytics provider widely used in clinical research, including clinical-grade actigraphy for digital endpoints. Comparable to VivoSense as a specialized wearable data provider for clinical trials, though more hardware-centric.

TypeEmerging player
Description

Decentralized clinical trial operator that integrates wearable sensors and remote data capture for sponsor studies. Comparable to VivoSense in its emphasis on wearable-derived digital endpoints in decentralized/hybrid trial designs.

TypeEmerging player
Description

Decentralized and hybrid clinical trial CRO with integrated wearable sensors and digital endpoints. Competes with VivoSense for sponsors seeking end-to-end DCT execution with wearable-derived outcomes.

TypeDirect peer
Description

Direct competitor offering a wearable sensor / digital biomarker platform and CRO-style services for clinical trials. Overlaps with VivoSense on device-agnostic sensor capture, digital endpoint validation, and pharma sponsor customers in respiratory and rare disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VivoSense

Clinical Research Services (Wearable Sensor CRO)vivosense.com

VivoSense is a specialized wearable sensor Contract Research Organization serving pharmaceutical sponsors, biotech firms, and digital health innovators with end-to-end wearable sensor implementation and digital endpoint services across clinical trials. Its proprietary cloud-based DHT platform and 14+ years of expertise support trials in 30+ countries and 20+ therapeutic areas.

What VivoSense does

VivoSense, Inc. is a privately held, specialized Wearable Sensor Contract Research Organization (CRO) founded in 2010 and headquartered in Newport Coast, California. The company serves pharmaceutical sponsors, biotech firms, traditional CROs, and digital health innovators by providing end-to-end services for implementing wearable and connected digital health technologies (DHTs) in clinical trials. These services span three integrated phases: Study Startup (DHT strategy, sensor selection, protocol development), Study Conduct (device operationalization, monitoring, data collection, and transfer), and Study Closeout (data investigation, statistical analysis, and clinical validation). Named customer engagements include argenx (Phase 3b case study presented at the 2025 Digital Biomarkers Summit), Genentech/Roche (Clinical Trial Innovation Summit collaboration), GSK, RSRT, Boston Children's Hospital, Biogen, Mayo Clinic, and Newron.

The company's core technology is a proprietary, device-agnostic, cloud-based DHT platform that ingests, cleans, synchronizes, analyzes, and interprets wearable sensor data. The platform is described as compliant and auditable for use in regulated clinical trial environments and is paired with deep domain expertise across more than 70 wearable sensors, 20 therapeutic areas, and operations spanning 30+ countries. A flagship productized asset is MEADOW-RETT-BR, a DHT-based measure of apnea events in Rett syndrome patients co-developed with the Rett Syndrome Research Trust and Boston Children's Hospital, which received positive feedback from the EMA Innovation Task Force in December 2024.

VivoSense operates a B2B professional services revenue model with project-based, quote-determined pricing tied to study scope, duration, sensor requirements, and geographic reach. The company has raised approximately $27 million across its lifetime, including a $25 million Series A in March 2022 led by Perceptive Xontogeny Venture Fund and Debiopharm Innovation Fund. Distribution is exclusively direct enterprise sales, supported by thought leadership content (website, blogs, eBooks, webinars, peer-reviewed publications in journals such as Karger Digital Biomarkers and Frontiers in Digital Health) and active participation in industry coalitions including DiMe, DATAcc, FNIH, CTTI, CancerX, and ISPOR. Leadership comprises co-founder and CEO Dudley Tabakin, CSO Kate Lyden PhD, CTO Doug McAllister, Chief Algorithm Officer Ralf Hempfling, and functional VPs across sales, marketing, finance, engineering, science, quality, and clinical operations.

VivoSense firmographics

Firmographics
Name
VivoSense
Legal name
VivoSense, Inc.
Website
https://vivosense.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
VivoSense is a specialized wearable sensor Contract Research Organization serving pharmaceutical sponsors, biotech firms, and digital health innovators with end-to-end wearable sensor implementation and digital endpoint services across clinical trials. Its proprietary cloud-based DHT platform and 14+ years of expertise support trials in 30+ countries and 20+ therapeutic areas.
Ownership category
akta.pro rank

VivoSense industry classification

Industry
Product category
Clinical Research Services (Wearable Sensor CRO)
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs

Keywords

  • Wearable sensor CRO
  • Digital health technology
  • Clinical trial services
  • Digital endpoint development
  • Wearable sensor analytics

Where VivoSense is headquartered

Location

Headquarters

HQ city
Newport Coast
HQ country
United States
HQ region
North America

Offices1 record

Markets served

VivoSense business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Wearable Sensor CRO Services: VivoSense generates revenue through providing end-to-end services for wearable sensor implementation in clinical trials. This includes DHT strategy consulting, sensor selection and operationalization, data collection and cleaning, and clinical validation services. The revenue model is project-based and service-oriented, working with pharmaceutical sponsors across clinical trial phases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

VivoSense product offering

Product offering

Core offering

VivoSense operates as a dedicated Wearable Sensor Contract Research Organization (CRO), providing end-to-end services and a proprietary cloud-based Digital Health Technology (DHT) platform for implementing wearable and connected digital health technologies in clinical trials. Its offering spans Study Startup (DHT strategy, measure selection, protocol development), Study Conduct (operationalization, monitoring, data collection, data transfer), and Study Closeout (data investigation, statistical analyses, clinical validation) for pharmaceutical sponsors, traditional CROs, and digital health innovators across more than 30 countries.

Product overview

VivoSense operates as a Wearable Sensor Contract Research Organization (CRO) providing end-to-end services for wearable and connected digital health technologies in clinical trials. The company offers its proprietary VivoSense DHT Platform as the core technology infrastructure, complemented by three integrated service phases: Study Startup (DHT Strategy, Measure Selection, and Protocol Development), Study Conduct (DHT Operationalization, Monitoring, Data Collection, and Data Transfer), and Study Closeout (DHT Data Investigation, Statistical Analyses, and Clinical Validation). The company also develops specific digital health measures such as MEADOW-RETT-BR for rare disease applications. This unified platform-plus-services model enables pharmaceutical sponsors to integrate wearable sensor technologies throughout the clinical development lifecycle.

Differentiator

Problem solved

Functional benefit

Products and services

  • VivoSense DHT Platform VivoSense's proprietary cloud platform for managing digital health technology implementation in clinical trials. It serves as a centralized location for DHT-related activities including data collection, cleaning, monitoring, analysis, and reporting, providing a compliant and auditable solution for wearable sensor data. Sold as part of VivoSense's wearable sensor CRO service engagements with pharmaceutical sponsors.
  • Study Startup Services DHT Strategy, Measure Selection, and Protocol Development services including sensor recommendation based on study needs and data quality, design of data collection and processing procedures, and digital health technology vendor relationship management to streamline clinical operations. Sold as part of VivoSense's wearable sensor CRO service engagements with pharmaceutical sponsors.
  • Study Conduct Services DHT Operationalization, Monitoring, Data Collection, and Data Transfer services utilizing the VivoSense Platform for device deployment, site training, compliance tracking, and continuous data capture and cleaning. Sold as part of VivoSense's wearable sensor CRO service engagements with pharmaceutical sponsors.
  • Study Closeout Services DHT Data Investigation, Statistical Analyses, and Clinical Validation services including feasibility assessment, treatment response evaluation, clinical validity establishment, and regulatory-ready reporting. Sold as part of VivoSense's wearable sensor CRO service engagements with pharmaceutical sponsors.
  • MEADOW-RETT-BR Digital Health Measure MEADOW-RETT-BR is an innovative digital health technology-based measure of apnea events in patients with Rett syndrome, developed by VivoSense with the Rett Syndrome Research Trust and Boston Children's Hospital and currently undergoing EMA qualification for regulatory acceptance. It represents a specific digital endpoint that VivoSense develops and validates for rare disease applications.

Quantifiable outcome

  • 99% data availability achieved in cystic fibrosis trial with 200 devices across 18 sites worldwide
  • +4 more outcomes

Companies that use VivoSense

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

VivoSense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

VivoSense partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered minor, flagship and core.

  • OCT UK & Ireland 2026 ConferenceminorGTM or Marketing Partner · 1 June 2026CEO Dudley Tabakin presented at OCT UK & Ireland 2026 conference in London, discussing barriers to wearable adoption in clinical trials and achieving regulatory acceptance for digital endpoints.
  • argenxflagshipStrategic or Co-development Partner · 1 June 2025Strategic partnership for end-to-end wearable sensor CRO services. Presented joint case study at 2025 Digital Biomarkers Summit showcasing how VivoSense's operational oversight improved Phase 3b study outcomes to 95.3% valid data days. Partnership spans strategy development, measure selection, operationalization, and regulatory strategy.
  • RocheminorGTM or Marketing Partner · 1 June 2025Host venue for the 8th Annual Digital Biomarkers in Clinical Trials Summit 2025. VivoSense and argenx presented joint case study at this flagship industry event.
  • Rett Syndrome Research Trust (RSRT)coreStrategic or Co-development Partner · 1 December 2024Partner in MEADOW-RETT-BR digital health measure qualification for Rett syndrome. Collaboration focused on developing DHT-based measure of apnea events to support regulatory qualification with EMA and advance novel therapies for rare disease.
  • Boston Children's HospitalcoreStrategic or Co-development Partner · 1 December 2024Clinical partner in MEADOW-RETT-BR measure development for Rett syndrome. Working with VivoSense and RSRT on qualification of DHT-based apnea measurement with EMA Innovation Task Force.
  • GenentechcoreStrategic or Co-development Partner · 1 October 2024CEO Dudley Tabakin led panel at Genentech's Clinical Trial Innovation Summit. Collaboration on digital biomarker implementation discussions with GSK and gRED representatives. VivoSense presented on the Wearable Sensor CRO model and digital measure adoption.
  • GSKminorStrategic or Co-development Partner · 1 October 2024Dr. Sachin Shah, Digital Biomarker Lead at GSK, participated in Genentech panel with VivoSense CEO, discussing operational demands of wearable sensor data at scale and regulatory submission approaches.
  • DiMe (Digital Medicine Society)coreStrategic or Co-development Partner · 1 June 2024VivoSense joined DATAcc DiMe project 'Building the Business Case for Digital Endpoints' - a joint collaboration between DiMe and FDA. Contributed to Digital Endpoints ROI Calculator, Value Framework, and Case Study Catalog. Active contributor to DiMe Projects including Playbook, Core Measures of Physical Activity, and Core Measures of Sleep.
  • DATAcc (Digital Health Measurement Collaborative Community)coreStrategic or Co-development Partner · 1 June 2024Collaborative community with FDA's Center for Devices and Radiological Health. VivoSense contributes to establishing shared industry benchmarks for evaluating ROI of digital endpoints in drug development. Partner includes Tufts and FDA.
  • FNIH (Foundation for the National Institutes of Health)coreStrategic or Co-development PartnerVivoSense is a member of both the Cancer and Neuroscience FNIH Biomarker Steering Committees. FNIH connects leading public and private organizations to accelerate biomedical breakthroughs through the Biomarkers Consortium.
  • CTTI (Clinical Trials Transformation Initiative)coreStrategic or Co-development PartnerVivoSense is committed to CTTI's mission to build better, faster clinical trials. CTTI convenes 80+ members and 500+ multi-stakeholder organizations to develop and drive adoption of practices increasing clinical trial quality and efficiency.
  • CancerXcoreStrategic or Co-development PartnerPublic-private partnership to boost innovation in cancer. Co-hosted by Moffitt Cancer Center and DiMe, alongside ONC and OASH. VivoSense participates to advance digital health technologies in oncology research.
  • ISPORminorStrategic or Co-development PartnerVivoSense participates in ISPOR, the leading global scientific organization for health economics and outcomes research. Promotes HEO/R excellence to improve decision-making for health globally.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

VivoSense competitors and assessment

Company assessment

Broad incumbents

  • Medidata (Dassault Systèmes): Enterprise clinical trial platform owned by Dassault Systèmes with sensor ingestion, eCOA, and decentralized trial capabilities via Rave. Competes with VivoSense at the platform layer for wearable data capture and analysis in pharma-sponsored trials.
  • IQVIA: World's largest CRO with expanding digital health, real-world evidence, and connected device capabilities. Overlaps with VivoSense in wearable sensor deployment and digital endpoint services, particularly across large global Phase III programs.
  • ICON plc: Top-tier global CRO with a growing digital endpoints and decentralized trials practice (post-PRA Health and Symphony Clinical Research integrations). Broad incumbent competing for the same wearable CRO budgets as VivoSense.
  • Clario: Large clinical trial technology company (formed from ERT and Bioclinica) offering eCOA, imaging, and increasingly wearable sensor / digital endpoint solutions to pharma sponsors. Broad incumbent competing with VivoSense in the digital endpoint layer of clinical trials.

Emerging players

  • Medable: Decentralized clinical trial technology platform with integrated eCOA, ePRO, and connected device / wearable sensor modules. Competes with VivoSense in enabling sponsors to operationalize wearable data in clinical trials, though more platform- and less service-led.
  • Science 37: Decentralized clinical trial operator that integrates wearable sensors and remote data capture for sponsor studies. Comparable to VivoSense in its emphasis on wearable-derived digital endpoints in decentralized/hybrid trial designs.
  • ObvioHealth: Decentralized and hybrid clinical trial CRO with integrated wearable sensors and digital endpoints. Competes with VivoSense for sponsors seeking end-to-end DCT execution with wearable-derived outcomes.

Others

  • Evidation Health: Real-world health data and digital measurement platform leveraging wearables and connected devices, with applications in clinical research and patient-generated evidence. Thematically adjacent to VivoSense's wearable data business, primarily outside the regulated clinical trial endpoint layer.

Direct peers

  • ActiGraph: Wearable sensor hardware and analytics provider widely used in clinical research, including clinical-grade actigraphy for digital endpoints. Comparable to VivoSense as a specialized wearable data provider for clinical trials, though more hardware-centric.
  • Koneksa Health: Direct competitor offering a wearable sensor / digital biomarker platform and CRO-style services for clinical trials. Overlaps with VivoSense on device-agnostic sensor capture, digital endpoint validation, and pharma sponsor customers in respiratory and rare disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VivoSense social profiles

Digital presence

VivoSense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VivoSense leadership team

Management profile

Number of profiles

Profiles9 records

VivoSense funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VivoSense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VivoSense

What does VivoSense do?

VivoSense operates as a dedicated Wearable Sensor Contract Research Organization (CRO), providing end-to-end services and a proprietary cloud-based Digital Health Technology (DHT) platform for implementing wearable and connected digital health technologies in clinical trials. Its offering spans Study Startup (DHT strategy, measure selection, protocol development), Study Conduct (operationalization, monitoring, data collection, data transfer), and Study Closeout (data investigation, statistical analyses, clinical validation) for pharmaceutical sponsors, traditional CROs, and digital health innovators across more than 30 countries.

Is VivoSense a public or private company?

VivoSense is a private company. It is classified as venture growth investor backed and is currently operating.

When was VivoSense founded?

VivoSense was founded in 2010. It employs 11 to 50 people.

Where is VivoSense based?

VivoSense is headquartered in Newport Coast, United States, in the North America region.

How does VivoSense make money?

One revenue line is on record: wearable Sensor CRO Services.

Who are VivoSense's main competitors?

Broad incumbents on record are Medidata (Dassault Systèmes), IQVIA, ICON plc and Clario. Emerging players are Medable, Science 37 and ObvioHealth. Evidation Health is listed as an others. Direct peers are ActiGraph and Koneksa Health.

Does VivoSense have an API?

No public API is recorded for VivoSense.

What industry is VivoSense in?

VivoSense's product category is Clinical Research Services (Wearable Sensor CRO). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooHow wearables can unlock their full potential in clinical researchDudley Tabakin, founder and CEO of wearable sensor data analytics company VivoSense, spoke at the OCT UK & Ireland 2026 conference in London about the untapped potential of wearable devices in clinical trials, noting that only about 1,000 of an estimated number of trials over 25 years have incorporated wearable sensors. He outlined key challenges including data quality issues, the "algorithm trap" where commercial wearable algorithms built on healthy populations can misinterpret data from diseased populations, and the absence of any digital endpoints yet serving as the primary basis for drug approval. Tabakin emphasized that successful implementation requires early protocol design, sensor selection, disease-specific algorithm adjustments, and early ongoing engagement with regulators to transform continuous wearable data into robust evidence that could reshape drug development.Clinical Trials ArenaHow wearables can unlock their full potential in clinical researchDudley Tabakin, CEO of VivoSense, argued at the OCT UK & Ireland 2026 conference that wearable technology remains underutilized in clinical trials despite its potential to provide continuous, patient-centered data. He highlighted significant implementation challenges, including data noise, algorithmic biases for diseased populations, and the lack of regulatory validation for digital endpoints as primary approval bases.VivosenseWearable Sensor CRO Partnership Case Study: Unlocking the Value of Digital EndpointsPharmaceutical company argenx partnered with wearable sensor CRO VivoSense to integrate digital health technologies into its clinical trials, establishing a dedicated DHT CORE team. This end-to-end partnership significantly improved data quality, raising the rate of valid data days from 54.82% in Phase 2 studies to 95.3% in a Phase 3b study. The collaboration also demonstrated that digital endpoints outperformed traditional clinical outcomes and accelerated regulatory readiness for rare disease indications.VivosenseSharing Wearable Sensor Data with Participants: Insights, Challenges, and Lessons LearnedVivoSense published a research article in Frontiers in Digital Health Journal exploring whether and how clinical trial sponsors should return individual wearable sensor results to participants, identifying benefits including enhanced engagement, trust, and participant empowerment.XontogenyVivoSense Announces Closing of $25M Series A FinancingVivoSense, Inc. announced the closing of a $25 million Series A financing round on March 30, 2022. The capital will be used to accelerate the development of digital biomarkers and expand its informatics platform for analyzing data from wearable sensors in clinical trials. The investment was provided by the Debiopharm Innovation Fund and the Perceptive Xontogeny Venture (PXV) Fund.SecSEC FORM DVivoSense, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing discloses a total offering amount of $25,000,000 USD, with two investors having already participated in the offering as of March 4, 2022. The company is based in Newport Coast, California.CB Insights100+ early-stage companies using digital biomarkers to improve patient careA report compiles over 100 early-stage companies using digital biomarkers — health data from implantable, portable or wearable devices — to support diagnostics, precision medicine and clinical trials. Examples cited include Looxid Lab's EEG and VR-based cognitive screening and VivoSense's connected wearables for trial data. The list was drawn from CB Insights data.OCNJ DailyRichard Hansen Discusses Recent Drug Safety NewsThe U.S. Food and Drug Administration has requested an $8.4 billion budget for 2023 to enhance drug safety, modernize technology, and address public health emergencies like the opioid crisis. Concurrently, Dragonfly Therapeutics appointed two senior leaders in pharmacovigilance and regulatory affairs, while VivoSense secured $25 million in funding to expand its biometric data collection tools for clinical trials.socaltech.comVivoSense Gets $25M For WearablesNewport Beach-based VivoSense has secured $25 million in Series A funding to support its development of an informatics platform for clinical trial data analysis. The investment was provided by Debiopharm and the Perceptive Xontogeny Venture (PXV) Fund, with proceeds designated to expand and refine the company's wearable sensor technology.